MedPath

Cytarabine

Cytarabine Injection

Approved
Approval ID

bc2fa221-ea56-48b8-8304-42cd81b8463b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 9, 2022

Manufacturers
FDA

Hospira, Inc.

DUNS: 141588017

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CYTARABINE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code61703-305
Application NumberANDA071868
Product Classification
M
Marketing Category
C73584
G
Generic Name
CYTARABINE
Product Specifications
Route of AdministrationINTRAVENOUS, INTRATHECAL, SUBCUTANEOUS
Effective DateDecember 9, 2022
FDA Product Classification

INGREDIENTS (5)

SODIUM CHLORIDEInactive
Quantity: 6.8 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
CYTARABINEActive
Quantity: 20 mg in 1 mL
Code: 04079A1RDZ
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cytarabine - FDA Drug Approval Details